SCM
AVTX icon

Stonepine Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Stonepine Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-524
Closed -$2.57M – 30
2021
Q4 		$2.57M Buy
524
+229
+78% +$1.37M 1.18% 18
2021
Q3 		$1.85M Buy
+295
New +$2.39M 0.84% 19
2020
Q3 		– Sell
-156
Closed -$1.17M – 18
2020
Q2 		$1.17M Buy
+156
New +$1.13M 2.27% 11

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Stonepine Capital Management's AVTX Position: Q1 2022 in Review

Stonepine Capital Management sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 524 shares — an estimated $2.57M sold.

Stonepine Capital Management first reported a position in AVTX in Q2 2020 and held it in 3 quarters. The position peaked at $2.57M in Q4 2021. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

  • Stonepine Capital Management reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Stonepine Capital Management sold 524 Avalo Therapeutics shares in Q1 2022, an estimated $2.57M.
  • Stonepine Capital Management first reported a position in Avalo Therapeutics in Q2 2020 and held it in 3 quarters.
  • Stonepine Capital Management's Avalo Therapeutics position peaked at $2.57M in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on Stonepine Capital Management's 13F filing for Q1 2022, filed 16 May 2022.